Log in

Relevant bibliographies by topics / Pharmaceutical Solutions

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Pharmaceutical Solutions'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical Solutions.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical Solutions"

1

EDMAN, PETER. "Pharmaceutical Formulations— Suspensions and Solutions." Journal of Aerosol Medicine 7, s1 (January 1994): S—3—S—6. http://dx.doi.org/10.1089/jam.1994.7.suppl_1.s-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

McKinnon, Barbara Thompson, and Kenneth E. Avis. "Membrane Filtration of Pharmaceutical Solutions." American Journal of Health-System Pharmacy 50, no. 9 (September 1, 1993): 1921–36. http://dx.doi.org/10.1093/ajhp/50.9.1921.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Russo, Nicole M. "Pharmaceutical Calculations — A Basic Review." Journal of Pharmacy Technology 18, no. 5 (September 2002): 257–59. http://dx.doi.org/10.1177/875512250201800506.

Full text

Abstract:

Objective: To review mathematical topics used in pharmaceutical preparation, specifically ratios and proportions, percentage concentrations, and stock solutions. Data Source: Online pharmaceutics sources and current pharmaceutics textbooks were consulted. Data Synthesis: Ratios and proportions are basic tools for adjusting drug concentrations. Using proportions, medications can be provided in any concentration desired. By extending this technique to percentage concentrations, prescriptions can be interpreted and calculated. In the same manner, the ability to dilute stock solutions provides patient-specific drug delivery. Conclusions: The mathematical concepts of ratios and proportions, percentage concentrations, and stock dilutions are essential for correct medication administration in any setting.

APA, Harvard, Vancouver, ISO, and other styles

4

Ivanova, S. V., M. A. Erganzhiev, and S. V. Murashova. "The Role of Intellectual Property in the Innovation Activities of Russian Pharmaceutical Companies." Economics. Law. Innovaion, no. 4 (December 29, 2022): 38–47. http://dx.doi.org/10.17586/2713-1874-2022-4-38-47.

Full text

Abstract:

The authors of the study analyze the role played by the intellectual property of domestic and foreign applicants in the Russian segment of the international pharmaceutical market, based on data on patent activity. Modern realities of the Russian pharmaceutical industry are formed under the influence of two multidirectional processes – protectionist policy and technology development in the format of open innovations, which influence the choice of tools for solving the problems of innovation management. Domestic patent holders began to take an increasingly tough stance against competitors from foreign countries, but they still lose to foreign pharmaceutical companies in the quantitative volume of protected technical solutions. The paper presents an analysis of patent applications filed with Rospatent and the Eurasian Patent Office related to the pharmaceutical industry. The authors assessed the share of patent applications in the field of medicine and pharmaceuticals in the total number of technical solutions submitted for registration. Con-clusions and recommendations for optimizing the management systems of Russian pharmaceutical companies and the development of domestic pharmaceuticals are made in relation to existing economic cycles. The changes that have taken place in the region over the past 11 years are identified, and directions for the development of the pharmaceutical industry are formulated.

APA, Harvard, Vancouver, ISO, and other styles

5

Gunjan Behl, Deepali Shahane, Baljeet Kaur, and Shambhu Rai. "Generic Adaptive Emergency Agile Model for Health care and Pharmaceuticals in crisis situation." Journal of Pharmaceutical Negative Results 13, no. 4 (November 10, 2022): 1167–71. http://dx.doi.org/10.47750/pnr.2022.13.04.163.

Full text

Abstract:

Pandemic challenges demanded immediate solutions and continues improvement in solutions on field which motivated the entire world’s research community to find an opportunity to provide speedy solutions to problems. Agile developments provide immediate improvements which functioned on the grounds of assorted health care units, medical facilities, pharmaceuticals and variants of COVID 19 cases. Agile developments proved its effectiveness for immediate solutions which take full advantage of aids to health and pharmaceutical organizations and also exploits worth rapport with health stakeholders. This springs a thirst for carrying out the study on agile developments and its effectiveness for health and pharmaceuticals so, the study focuses to design generic adaptive emergency agile model for Health care and pharmaceuticals to deal with Crisis pressure which will support COVID 19 medical research field.

APA, Harvard, Vancouver, ISO, and other styles

6

Ayala, Alejandro Pedro. "Pharmaceutical solid solutions of antiretroviral drugs." Acta Crystallographica Section A Foundations and Advances 73, a2 (December 1, 2017): C113. http://dx.doi.org/10.1107/s205327331709458x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ahuja, S. "Chromatographic solutions to pharmaceutical analytical problems." Chromatographia 34, no. 5-8 (September 1992): 411–16. http://dx.doi.org/10.1007/bf02268376.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nazzini, Renato. "Parallel Trade in the Pharmaceutical Market – Current Trends and Future Solutions." World Competition 26, Issue 1 (March 1, 2003): 53–74. http://dx.doi.org/10.54648/woco2003008.

Full text

Abstract:

This article explores the relationship between EU law and the pharmaceutical market. It analyses the political debate on the competitiveness of the European pharmaceutical industry, in the view of the enlargement, the different models of regulation of pharmaceuticals in the Member States and the economic theories of parallel trade and intellectual property rights. Against this background, it is demonstrated that both the Commission and the Court of Justice have adopted a strong pro-single market approach, whereby price regulations, ethical obligations to sell medicines and the need for adequate reward of investment in research and development have been considered incapable of limiting the scope of application of the European law of competition and free movement of goods. The article suggests solutions available under the existing legal framework; it also proposes, in view of further European harmonisation, the principle of effective and fair negotiation as a core element in price regulation in the Member States.

APA, Harvard, Vancouver, ISO, and other styles

9

Deshkar, Anuradha T., Ujwala P. Gawali, and Prashant A. Shirure. "Environmental pharmacology: an emerging science." International Journal of Basic & Clinical Pharmacology 7, no. 3 (February 22, 2018): 359. http://dx.doi.org/10.18203/2319-2003.ijbcp20180645.

Full text

Abstract:

With continuous rapid expansion of the human population there is escalating demand for resources, including human and veterinary pharmaceuticals. This has lead to rapid development of global pharmaceutical industry and with that increase in issues caused by pharmaceutical products. In recent years a great concern has been expressed over the occurrence and persistence of pharmaceutical products in the environment and their potential impact on environment. Owing to this the new branch of science called environmental pharmacology has sprouted. Environmental pharmacology deals with dispersion and impact of pharmaceutical products on environment. Solutions need to be suggested to save this only liveable planet from ill effects of these pharmaceutical products. This has given birth to the science of Ecopharmacovigilance (EPV).

APA, Harvard, Vancouver, ISO, and other styles

10

Pedro, Sónia N., Carmen S. R. Freire, Armando J. D. Silvestre, and Mara G. Freire. "The Role of Ionic Liquids in the Pharmaceutical Field: An Overview of Relevant Applications." International Journal of Molecular Sciences 21, no. 21 (November 5, 2020): 8298. http://dx.doi.org/10.3390/ijms21218298.

Full text

Abstract:

Solubility, bioavailability, permeation, polymorphism, and stability concerns associated to solid-state pharmaceuticals demand for effective solutions. To overcome some of these drawbacks, ionic liquids (ILs) have been investigated as solvents, reagents, and anti-solvents in the synthesis and crystallization of active pharmaceutical ingredients (APIs), as solvents, co-solvents and emulsifiers in drug formulations, as pharmaceuticals (API-ILs) aiming liquid therapeutics, and in the development and/or improvement of drug-delivery-based systems. The present review focuses on the use of ILs in the pharmaceutical field, covering their multiple applications from pharmaceutical synthesis to drug delivery. The most relevant research conducted up to date is presented and discussed, together with a critical analysis of the most significant IL-based strategies in order to improve the performance of therapeutics and drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Pharmaceutical Solutions"

1

Dabros, Marta. "Pharmaceutical Polymorphs, Cocrystals and Solid Solutions." Digital WPI, 2009. https://digitalcommons.wpi.edu/etd-dissertations/30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lawson, Sarah, Stacy D. Brown, Paul Lewis, and Gina Peacock. "Comparative Stability of Oral Vitamin K Solutions Stored in Refrigerated Amber Plastic Syringes." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/etsu-works/5264.

Full text

Abstract:

Purpose: Vitamin K1 (phytonadione) is a fat-soluble vitamin and an essential cofactor for the synthesis of clotting factors II, VII, IX, X, protein C, and protein S. Vitamin K antagonists deplete vitamin K reserves effectively preventing the synthesis of these clotting factors leading to anticoagulation. Overly excessive anticoagulation, as evidenced by INRs greater than 5, may necessitate vitamin K for reversal of warfarin depending on bleeding risk factors. For elevated INR without bleeding, the oral route is preferred. Orally administered vitamin K1 tablets are only supplied by a single manufacturer, and only available as a 5 mg tablet. Concerns with availability of this tablet, lack of dosing options for treatment requiring less than 5 mg, and delivery options for patients unable to swallow whole tablets have prompted the exploration of alternative dosing strategies using the 10 mg/mL injectable emulsion compounded into an oral liquid. The possibility of storing the oral liquid in unit-doses adds a layer of convenience, and is common practice in many hospital pharmacies. In this project, we compared oral liquid vitamin K1 in sterile water for injection (SWFI) to oral liquid vitamin K1 in Ora-Sweet, simple syrup, cherry syrup, and Syrpalta stored in amber plastic oral syringes. Methods: Batches of 1 mg/mL vitamin K1 were prepared in SWFI, Ora-Sweet, simple syrup, cherry syrup, and Syrpalta and drawn up by 1-mL aliquots into amber plastic oral syringes. Syringes were capped and stored in a laboratory refrigerator (4.9-5.4oC). for the duration of the study. On each study day (0, 1, 2, 4, 7, 14, 21, 30, 60, and 90), three syringes from each vehicle were removed, and the contents diluted with ethanol to achieve a 0.5 mg/mL assay concentration. Additionally, USP reference material was used on each study day to prepare a fresh 0.5 mg/mL reference solution. The samples and reference were analyzed using a previously validated HPLC-UV method. Results were compared using a 2-way ANOVA (p = 0.05) with post-hoc Tukey’s correction for multiple comparisons. Product stability was defined as 90-110% labeled amount. Results: Of the vehicles tested, SWFI was the most suitable vehicle for longer-term storage of unit-dosed vitamin K1. The 1 mg/mL vitamin K1 in SWFI, when stored in amber plastic oral syringes, remains within the acceptable 90 – 110% range for 21 days. The Syrpalta preparation demonstrated the next highest BUD of 7 days, with one syringe (2 injections) falling outside the 90% potency at the 14 day time point. Cherry syrup allowed for very limited stability, with a BUD of 24 hours. By the 48-hour time point, two of the three samples were below the 90% potency cutoff. For the vitamin K oral solutions prepared in simple syrup and Ora-Sweet, the recovery of vitamin K was not within acceptable limits, even on the day of compounding. The initial recovery for vitamin K in simple syrup was only 86.8%. Similarly, the preparation in Ora-Sweet, was not at acceptable potency on the day of compounding, (92.7 ± 9.9%). While the average recovery in Ora-Sweet exceeded 90%, the variability between samples suggests a lack of homogeneous distribution of drug through the vehicle. Statistically significant differences were detected between the SWFI preparation and all other vehicles in a 2-way ANOVA with Tukey’s multiple comparison post-test (p-value of 0.05). This difference was most pronounced between SWFI and Ora-Sweet and SWFI and simple syrup (both p < 0.0001). Cherry syrup was also vastly different from SWFI (p = 0.0002), and the difference between SWFI and Syrpalta was less pronounced, yet still significant (p = 0.0442). Conclusion: Vitamin K1 in sterile water and Syrpalta was stable for 21 days and 7 days, respectively, when stored in amber plastic syringes. Vitamin K1 in cherry syrup was only stable for 24 hours in the syringes. For vitamin K1 in Ora-Sweet and simple syrup, the within-day variability was very high due to limitations in drug dissolution; as such the average recovery was not consistently above 90%, even on the day of compounding. Statistically significant differences were detected between the SWFI formulation and all other vehicles. Several factors appear to affect the potency and stability of vitamin K1 in different vehicles. Because the stability of vitamin K1 oral solution differs between storage in amber glass bottles and oral syringes, vitamin K1 may have the potential to adsorb to polypropylene (PPE). The pH of the vehicle may contribute to degradation of vitamin K1, and the viscosity of the vehicle may affect the achievable potency of certain mixtures. The viscosity of the mixture also appears to affect maintenance of a homogenous mixture, but the presence of alcohol in the vehicle may help aid in solubilizing the vitamin K1 in Syrpalta. Vitamin K1 in SWFI appears to be the most suitable vehicle for longer-term storage of unit-dosed vitamin K, but Syrpalta and cherry syrup may also be appropriate for more immediate use.

APA, Harvard, Vancouver, ISO, and other styles

3

Pinsuwan, Sirirat 1961. "Stability kinetics of 4-dedimethylamino sancycline, a new anti-tumor drug, in aqueous solutions." Diss., The University of Arizona, 1998. http://hdl.handle.net/10150/282753.

Full text

Abstract:

4-Dedimethylamino sancycline (col-3) is a new antitumor antibiotic of the tetracycline family. Preformulation studies have indicated that col-3 is not stable in aqueous solutions. The overall purpose of this research project is to investigate the stability kinetics of this drug in aqueous solutions. The physicochemical properties of col-3, including melting point, UV spectrum, mass spectrum, dissociation constants and solubility were determined. Col-3 is an acidic compound with two pKₐ values of 5.9 (pKₐ₁) and 8.1 (pKₐ₂). It is slightly soluble in water (0.01 mg/mL) and readily soluble in organic solvents such as polyethylene glycol and benzyl alcohol. Although the solubility of col-3 increases with increasing pH, its stability decreases with increasing pH. A HPLC assay was developed to quantitate col-3 and separate its degradation products. Four major degradation products of col-3 were detected under alkaline conditions. These degradates were identified by their elution times and their UV-absorption spectra. The kinetics of degradation of col-3 in aqueous solution at 25°C were investigated by HPLC over the pH-range of 2-10. The Influence of pH, buffer concentration, light, temperature and some additives on the degradation rate were studied. The degradation of col-3 was found to follow first-order kinetics at 25°C. A rate expression covering the degradation of the various ionic forms of the drug was derived and shown to account for the shape of the experimental pH-rate profile. Under basic conditions, the degradation of col-3 involves oxidation, which is catalyzed by metal ions. The separation of the four initial degradation products of col-3 was investigated. Partial separation of these compounds is achieved by liquid-liquid extraction. However, due to the instability of these compounds, their complete isolation cannot be successful. The UV spectroscopic analysis of these compounds shows that an absorbance at 360 nm is partially decreased in degradates I and II and totally absent in degradates III and IV. These results suggest that the phenolic diketone moiety, which produces this absorption band, has been altered upon degradation.

APA, Harvard, Vancouver, ISO, and other styles

4

Boca, Madalina Brindusa. "Research into process validation in pharmaceutical companies, with specific reference to Roche, South Africa." Pretoria : [s.n.], 2009. http://upetd.up.ac.za/thesis/available/etd-10132009-181630/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kerr, Helen Rosemary. "The surface properties of hyaluronic acid solutions in relation to joint lubrication." Thesis, University College London (University of London), 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308428.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lawson, Sarah, and Stacy Brown. "Stability of Oral Vitamin K Solutions Stored in Amber Plastic Syringes." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/asrf/2018/schedule/102.

Full text

Abstract:

Oral vitamin K is administered to patients who have very high INR lab values and are on warfarin therapy. Due to the inability of some patients to swallow tablets, and the commercial formulation of vitamin K being available only as a tablet or an injectable emulsion, it may be necessary to compound an oral liquid formulation. When compounding batches of oral solutions, it is sometimes convenient to measure the product in unit doses. In this project, we compared liquid vitamin K in sterile water (1mg/mL) verses liquid vitamin K in Ora-Sweet (1mg/mL) stored in amber plastic syringes. Vitamin K is light sensitive and is best stored in amber containers. Vitamin K is also lipophilic and may adsorb to the plastic syringes. In this study, we investigated the feasibility of bulk compounding oral vitamin K solutions, and aliquoting them for storage in amber plastic syringes. The Vitamin K in sterile water syringes were made by mixing 45 mL of sterile water and 5 ampules, each containing 10mg/mL of vitamin K emulsion, together in an amber glass bottle for a final concentration of 1mg/mL. Thirty 1mL plastic amber syringes were filled with the mixture, capped, and placed in the refrigerator. The same process was repeated using Ora-Sweet instead of sterile water to fill thirty more plastic amber syringes. Three syringes of vitamin K in sterile water mixture, three syringes of vitamin K in Ora-Sweet mixture, and one Vitamin K reference standard were all analyzed using HPLC-UV on the day of compounding, and at day 1, 2, 4, 7, 14, 21, 30, 60, and 90. If stability is defined as 90-110% active ingredient, then Vitamin K in sterile water is stable to fourteen days, 95.3±3.5% recovery, but some samples fell below 90% recovery after 14 days. By day ninety, the recovery in SWFI syringes was 84.2±8.9%. For vitamin K in Ora-Sweet, the within-day variability was very high due to limitations in drug dissolution; as such the average concentration was not consistently above 90%. On the day of compounding, the percent recovery in the Ora-Sweet syringes was 92.7±9.9%, despite 1 hour of stirring. In conclusion, the Vitamin K in sterile water mixture can be stored in refrigerated, amber oral plastic syringes for 14 days, but plastic amber syringes were not appropriate for storage of the Vitamin K in Ora-Sweet mixture.

APA, Harvard, Vancouver, ISO, and other styles

7

Thomas, P. H. "Studies on the pharmaceutical and clinical problems associated with the storage and administration of intravenous solutions." Thesis, Cardiff University, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.372586.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Brown, Stacy D., and Paul Lewis. "Stability Evaluation of Unit-Dose Vancomycin Hcl Oral Solutions in Plastic Capped Oral Syringes and Plastic Sealed Dosing Cups." Digital Commons @ East Tennessee State University, 2018. https://dc.etsu.edu/etsu-works/5263.

Full text

Abstract:

Purpose: Oral vancomycin is a first-line treatment for Clostridium difficile-associated diarrhea. Preparation of oral vancomycin solutions historically has been facilitated by extemporaneous compounding, using various formulas or compounding kits, such as FIRST® - Vancomycin. More recently, FIRVANQ™ (vancomycin HCl) for oral solution was approved by the FDA, replacing the FIRST® compounding kits. Preparation and storage of unit-doses of oral solutions can expedite delivery of the medication to the patient and reduce opportunity for dosing errors. In this study, we evaluated the stored stability of two preparations of vancomycin HCl oral solution (FIRST® – Vancomycin and FIRVANQ™), stored in oral syringes and dosing cups at refrigerated and room temperatures. Methods: Triplicate batches of vancomycin HCl oral solution (50 mg/mL) were prepared using FIRST® - Vancomycin and FIRVANQ™, aliquoted into plastic oral syringes and sealed dosing cups, and stored at refrigerated and room temperatures for a total of six batches. Additionally, remaining samples from FIRVANQ™ batches were unit-dosed in clear Luer-Lok™ syringes and stored under refrigeration as a seventh batch. Samples were removed and analyzed for vancomycin recovery using a previously validated high-performance liquid chromatography with ultraviolet detection (HPLC-UV) method over a 30-day period. Recovery was quantitatively assessed by comparing to a freshly prepared United States Pharmacopoeia (USP) reference standard on each day of sampling. Results: Stability was defined as recovery of 90 - 110% of labeled amount. For all tested samples, the chemical potency remained within the therapeutically acceptable window for the entire study period of 30 days. At room temperature, the FIRST® syringes and cups both retained 95% potency after 30 days. Under refrigeration, this product retained 100% potency and 91% potency in syringes and cups, respectively. Similarly, the FIRVANQ™ room temperature syringes were at 99% recovery and the room temperature cups at 95% recovery after 30 days. Refrigerated FIRVANQ™ retained a potency of 102% potency in the dosing cups after 30 days, and the both syringes types (clear and amber) were 97% and 101%, respectively, recovery during the study period. Conclusion: The percent recovery of vancomycin in each test group remains within 90 – 110% of the labeled amount throughout duration of study (0 – 30 days). Based on this study, unit-dosing has been shown to have a 30-day chemical stability. In this case, unit-dosing not only may be used to improve workflow and reduce dosing errors, but may also have an impact of reducing drug waste due to avoidance of discarding appropriately potent drug product. Additionally, stability within the study period was independent of storage container and condition. Finally, this unit-dosing practice for FIRVANQ™ is equally acceptable in the classic luer-slip amber plastic syringes, and the newer Luer-Lok™ clear plastic syringes.

APA, Harvard, Vancouver, ISO, and other styles

9

Méndez, del Río José Ricardo. "Solubility and phase transitions in batch and laminar-flow tubular crystallizers." Available online, Georgia Institute of Technology, 2004:, 2004. http://etd.gatech.edu/theses/available/etd-11182004-120908/unrestricted/mendezdelrio%5Fjose%5Fr%5F200412%5Fmast.pdf.

Full text

Abstract:

Thesis (M.S.)--Chemical Engineering, Georgia Institute of Technology, 2005.
Ronald W. Rousseau, Committee Chair ; William J. Koros, Committee Member ; Angus P. Wilkinson, Committee Member ; David J. am Ende, Committee Member. Includes bibliographical references.

APA, Harvard, Vancouver, ISO, and other styles

10

Barthe, Stephanie Cecile. "Investigation and modeling of the mechanisms involved in batch cooling crystallization and polymorphism through efficient use of the FBRM." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2008. http://hdl.handle.net/1853/24752.

Full text

Abstract:

Thesis (Ph.D.)--Chemical Engineering, Georgia Institute of Technology, 2009.
Committee Chair: Dr Rousseau, Ronald W; Committee Co-Chair: Dr Grover Gallivan, Martha; Committee Member: Dr Realff, Matthew; Committee Member: Dr Garmestani, Hamid; Committee Member: Dr Nenes, Athanasios.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Pharmaceutical Solutions"

1

Pharmaceutical dosage forms: Parenteral medications. 3rd ed. London: Informa Healthcare, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pharmaceutical particulate matter: Analysis and control. Buffalo Grove, IL: Interpharm, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

1918-, Avis Kenneth E., Lieberman Herbert A. 1920-, and Lachman Leon 1929-, eds. Pharmaceutical dosage forms: Parenteral medications. 2nd ed. New York: M. Dekker, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Curren, Anna M. Math for meds: Dosages & solutions. 9th ed. Australia: Thomson/Delmar Learning, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

E, Weaver Mabel, Koehler Vera J, and Weaver Mabel E, eds. Weaver & Koehler's programmed mathematics of drugs and solutions. 5th ed. Philadelphia: Lippincott, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Norville, Mary Ann Fravel. Drug dosages and solutions. 3rd ed. Norwalk, Conn: Appleton & Lange, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

D, Munday Laurie, ed. Math for meds: Dosages and solutions. 7th ed. San Diego, CA: W.I. Publications, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Math for meds: Dosages and solutions. 8th ed. San Diego, CA: W.I. Publications, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Math for meds: Dosages and solutions. Australia: Delmar/Cengage Learning, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Duff, Deborah Lynn. A metric guide for health professionals on dosages & solutions. 3rd ed. Toronto, Ont: Saunders, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Pharmaceutical Solutions"

1

Savva, Michalakis. "Isotonic Solutions." In Pharmaceutical Calculations, 157–80. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-20335-1_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lam, Herman. "LC-MS for Pharmaceutical Analysis." In Therapeutic Delivery Solutions, 315–34. Hoboken, NJ: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118903681.ch11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ballantyne, Peri J., Kath Ryan, and Paul Bissell. "(Developing) pharmaceutical solutions to COVID-19." In Living Pharmaceutical Lives, 187–204. Milton Park, Abingdon, Oxon ; New York, NJ : Routledge, 2021. | Series: Routledge studies in the sociology of health and illness: Routledge, 2021. http://dx.doi.org/10.4324/9780429342868-13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Savva, Michalakis. "Dilution and Concentration of Pharmaceutical Solutions and Other Physical Mixtures." In Pharmaceutical Calculations, 93–112. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-20335-1_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Baxter, Thomas, and James Prescott. "POWDER PROCESS CHALLENGES AND SOLUTIONS." In Chemical Engineering in the Pharmaceutical Industry, 53–79. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2019. http://dx.doi.org/10.1002/9781119600800.ch53.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Al-Essa, Reem K., Mohammed Al-Rubaie, Stuart Walker, and Sam Salek. "The Strategic Planning Process of the GCC Regulatory Authorities: Barriers and Solutions." In Pharmaceutical Regulatory Environment, 205–29. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-17590-4_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hesse, Galina. "Developing Commercial Solutions for Therapeutic Proteins." In Value Creation in the Pharmaceutical Industry, 182–201. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2016. http://dx.doi.org/10.1002/9783527693405.ch9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stauffer, Fanny, Pierre-François Chavez, Julie Fahier, Corentin Larcy, Mehrdad Pasha, and Gabrielle Pilcer. "Challenges and Solutions in Drug Product Process Development from a Material Science Perspective." In Optimization of Pharmaceutical Processes, 413–35. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90924-6_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fangaia, Sónia I. G., Pedro M. G. Nicolau, Fernando A. D. R. A. Guerra, V. M. M. Lobo, and Ana C. F. Ribeiro. "Effect of Light on Transport of Potassium Thiocyanate in Aqueous Solutions." In Applied Pharmaceutical Practice and Nutraceuticals, 181–90. First edition.: Apple Academic Press, 2021. http://dx.doi.org/10.1201/9781003054894-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Schenck, Luke, Gregory M. Troup, Mike Lowinger, Li Li, and Craig McKelvey. "Achieving a Hot Melt Extrusion Design Space for the Production of Solid Solutions." In Chemical Engineering in the Pharmaceutical Industry, 819–36. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470882221.ch42.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical Solutions"

1

Yevtushenko, O. V., А. О. Siryk, and А. М. Okhmakevych. "Statistical aspects of occupational injuries in the manufacture of main pharmaceutical products and pharmaceutical preparations." In SCIENCE, ENGINEERING AND TECHNOLOGY: GLOBAL TRENDS, PROBLEMS AND SOLUTIONS. Baltija Publishing, 2021. http://dx.doi.org/10.30525/978-9934-26-046-9-56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kuznetsova, K. S., Z. E. Eremenko, A. I. Shubnyi, V. V. Glamazdin, and M. P. Natarov. "Dielectrometry of pharmaceutical ingredient solutions at microwaves." In 2017 IEEE First Ukraine Conference on Electrical and Computer Engineering (UKRCON). IEEE, 2017. http://dx.doi.org/10.1109/ukrcon.2017.8100487.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cristina-Luiza, Cristina-Luiza. "EU LEGISLATIVE SOLUTIONS REGARDING ENVIRONMENTAL RISK OF PHARMACEUTICAL PRODUCTS." In SGEM2017 17th International Multidisciplinary Scientific GeoConference and EXPO. Stef92 Technology, 2011. http://dx.doi.org/10.5593/sgem2017/54/s23.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rodríguez-Torres, M. Del P., L. A. Diaz -Torres, M. Olmos-López, P. Salas, and Clara Gutiérrez. "UVA mediated synthesis of gold nanoparticles in pharmaceutical-grade heparin sodium solutions." In SPIE NanoScience + Engineering, edited by Mark I. Stockman. SPIE, 2013. http://dx.doi.org/10.1117/12.2024441.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dolomakin, Y. Y. "Determination of the boundary shear stress of the two-phase system on the example of a pharmaceutical mixture." In SCIENCE, ENGINEERING AND TECHNOLOGY: GLOBAL TRENDS, PROBLEMS AND SOLUTIONS. Baltija Publishing, 2020. http://dx.doi.org/10.30525/978-9934-588-79-2-1.30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bilyi, Olexander I., Vasyl B. Getman, Fedir A. Konyev, Olexander Sapunkov, and Pavlo G. Sapunkov. "Devices for monitoring content of microparticles and bacterium in injection solutions in pharmaceutical production." In International Conference on Optoelectronic Information Technologies, edited by Sergey V. Svechnikov, Volodymyr P. Kojemiako, and Sergey A. Kostyukevych. SPIE, 2001. http://dx.doi.org/10.1117/12.429715.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Costa, Luciana, Bruna Vale, Cristhiane Reis, Joyce Andrade, Josiane Mattoso, Igor Silva, and Marcelo Brandão. "Microbial profile of intermediate process solutions identified by bioburden test in a pharmaceutical industry." In International Symposium on Immunobiological. Instituto de Tecnologia em Imunobiológicos, 2021. http://dx.doi.org/10.35259/isi.2021_46592.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

D’Imperio, Mariapaola, and Ferdinando Cannella. "Design of a Totally Robotic Solution for Sampling in Pharmaceutical Industry." In ASME 2019 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/detc2019-97734.

Full text

Abstract:

Abstract Quality control in the pharmaceutical industries is a critical issue. It consists of a sampling phase and an analysis phase. There are different ways of taking a sample to be submitted for a quality control: from static to dynamic methods, from simple to more complex solutions. All these traditional procedures and their results are strictly dependent on the operator, due to the fact that this type of environment is unstructured and not very often robotised. For this reason, the aim of the paper is to push forward the state of art in the sampling methods for quality controls, by presenting a totally robotic solution in the framework of dust samples collection from closed containers.

APA, Harvard, Vancouver, ISO, and other styles

9

Jureidini, J., and S. Coulombe. "Optimization of an atmospheric pressure direct-contact DBD for the treatment of aqueous pharmaceutical solutions." In The 33rd IEEE International Conference on Plasma Science, 2006. ICOPS 2006. IEEE Conference Record - Abstracts. IEEE, 2006. http://dx.doi.org/10.1109/plasma.2006.1707083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Haddad, Sandra. "Developing an E-Business system to improve the downstream pharmaceutical supply chain (A study on the Egyptian market)." In The 8th International Conference on Advanced Materials and Systems. INCDTP - Leather and Footwear Research Institute (ICPI), Bucharest, Romania, 2020. http://dx.doi.org/10.24264/icams-2020.iii.7.

Full text

Abstract:

Pharmaceutical products are considered sensitive products that require a well-managed distribution channel as they impact human lives. The aim of this research is to investigate the applicability of improving the downstream of the pharmaceutical supply chain (distribution channel) in Egypt through developing an E-business system. The study has adopted a deductive approach. Qualitative and quantitative methodologies were followed respectively. Qualitative in-depth interviews were conducted to get a better understanding of the situation in Egypt followed by a structured survey to test and verify the significance and the relation of the extracted variables using statistical tools. This resulted in highlighting significant variables impacting the relationship between pharmaceutical retailers (pharmacies) and consumers and the applicability of introducing an e-business retailing application that improves downstream chain performance by facilitating transactions i.e. easily locating the required medicine, matching consumers and retailers and spotting the inventory level in the distribution channel for better management solutions.

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical Solutions"

1

Mukungu, Andrew, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. Evaluating and Understanding the Reason for an Increase in Nonconformances in the Laboratory. Purdue University, November 2021. http://dx.doi.org/10.5703/1288284317430.

Full text

Abstract:

This is a study of nonconformances experienced by a laboratory of a pharmaceutical manufacturing facility in East Africa. There has been an increase in nonconformances from 216 nonconformances in 2017 to 229 in 2018 and by September 2019, 306 nonconformances were already logged. Increasing nonconformances result in delayed release of tested materials and many resources are wasted (e.g. chemicals, man hours and equipment). Analysts become frustrated, which may result in inexhaustive investigations. Understanding the reason for the increase in nonconformances will enable the facility to derive effective solutions to the identified causes, hence reducing the number of nonconformances and improving the productivity and morale of employees. This quantitative, nonexperimental, longitudinal survey study was intended to evaluate and understand the reason for increasing nonconformances. Trends of the nonconformances, previous investigations, procedure for investigation and the training given to analysts have been reviewed. Laboratory incidences were the most recurring nonconformances; and these were mainly caused by analyst errors. Corrective and Preventive Actions (CAPAs) were derived by cross functional teams whenever root causes were identified. Procedure for investigation of nonconformances refers to investigative tools. Identification of root causes to nonconformances recently became mandatory. Analysts have limited advanced industrial training on investigation of nonconformances. Another study should be carried out to understand the cause of analyst errors. The study can be rolled out to other departments at the manufacturing facility to create similar improvements. Analysts should enroll into advanced courses of industrial pharmacy to gain advanced industrial skills which they can apply in investigations to find root causes to nonconformances.

APA, Harvard, Vancouver, ISO, and other styles

2

O'Donnell, Kevin, and Anne Greene. A Risk Management Solution Designed to Facilitate Risk-Based Qualification, Validation, and Change Control Activities within GMP and Pharmaceutical Regulatory Compliance Environments in the EU—Part I. Institute of Validation Technology, July 2006. http://dx.doi.org/10.1080/21506590.wp7132006agko-rmsdfrbq.

Full text

Abstract:

A risk management solution is described that is designed to facilitate risk-based qualification, validation, and change control activities within GMP and regulatory compliance environments in the EU. This solution is based upon a set of pre-defined, fundamental principles and design criteria, which were considered important. It offers a documented and ready-to-use ten-step process for determining and managing, on a risk basis, the scope and extent of qualification and validation, and the likely impact of changes.

APA, Harvard, Vancouver, ISO, and other styles

3

O'Donnell, Kevin, and Anne Greene. A Risk Management Solution Designed to Facilitate Risk-Based Qualification, Validation, and Change Control Activities within GMP and Pharmaceutical Regulatory Compliance Environments in the EU—Part II. Institute of Validation Technology, July 2006. http://dx.doi.org/10.1080/21506590.wp7142006agko-rmsdii.

Full text

Abstract:

highlight the need for patient-focused and value-adding qualification, validation, and change control programmes for manufacturing and regulating medicinal products in the EU, which are cost-effective and in-line with current regulatory requirements and guidance. To this end, a formal risk management solution was presented that seeks to demonstrate, in a practical way, how Regulators and Industry in the EU may achieve these goals. This solution represents a formal and rigorous approach to risk management, offering a scientific and practical means for determining and managing, on a risk basis, the scope and extent of qualification and validation, and the likely impact of changes. Based on a ten-step, systematic process, this approach offers a ready-to-use and documented risk management methodology for these activities. This tool is not intended for use in all situations, or to address all risk areas or concerns encountered in GMP and Regulatory Compliance environments. Rather, its use should be commensurate with the complexity and/or criticality of the issue to be addressed, and in many instances, and in-line with ICH Q9 principles, a more informal approach to risk management may be more useful, and indeed proportionate.

APA, Harvard, Vancouver, ISO, and other styles

4

Zhang, Cheng, and Yue Yang. Impact of adaptive design on reducing the duration of clinical trials in rare cancers: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0081.

Full text

Abstract:

Review question / Objective: Whether the application of adaptive design in clinical trials of rare cancers can shorten the duration of clinical trials? Condition being studied: Currently, the development of innovative drug products (InMPs) for rare cancers faces many challenges, including the difficulty of enrolling sufficient numbers of patients from small and heterogeneous patient populations for clinical trials, and the significant risks of high financial investment, long development times and potential failure from a pharmaceutical company's perspective for rare cancer drugs due to limited knowledge of the natural history of the disease. Therefore, alternative approaches to clinical trial design are needed to conduct cost-effective, well-controlled analyses that can assess treatment effects in small, heterogeneous populations within shorter time frames. Adaptive trials, on the other hand, may be an effective solution to this problem. Adaptive clinical trials are designed to accelerate the clinical trial process by making predefined adjustments to key parameters through data accumulated at predefined time points during the trial without compromising the integrity and validity of the results.This study aims to examine the value of adaptive design in reducing the duration of clinical trials in rare cancers and encourage their wider implementation.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!